TitleClinical Associate Professor
InstitutionBaylor College of Medicine
DepartmentDepartment of Medicine
AddressOne Baylor Plaza
Houston, TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Leon MB, Mauri L, Popma JJ, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, McLaurin BT, Solomon SL, Douglas JS, Ball MW, Caputo RP, Jain A, Tolleson TR, Reen BM, Kirtane AJ, Fitzgerald PJ, Thompson K, Kandzari DE, ENDEAVOR IV Investigators. A randomized comparison of the Endeavor zotarolimus-eluting stent versus the TAXUS paclitaxel-eluting stent in de novo native coronary lesions 12-month outcomes from the ENDEAVOR IV trial. J Am Coll Cardiol. 2010 Feb 09; 55(6):543-54. PMID: 20152559.
      Citations: 39     Fields:    Translation:Humans
    2. Leon MB, Kandzari DE, Eisenstein EL, Anstrom KJ, Mauri L, Cutlip DE, Nikolsky E, O'Shaughnessy C, Overlie PA, Kirtane AJ, McLaurin BT, Solomon SL, Douglas JS, Popma JJ, ENDEAVOR IV Investigators. Late safety, efficacy, and cost-effectiveness of a zotarolimus-eluting stent compared with a paclitaxel-eluting stent in patients with de novo coronary lesions: 2-year follow-up from the ENDEAVOR IV trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions). JACC Cardiovasc Interv. 2009 Dec; 2(12):1208-18. PMID: 20129547.
      Citations: 11     Fields:    Translation:Humans
    3. Lev EI, Tayyan N, Raizner AE, Solomon SL, Simmons D, Kleiman NS. Initial impact of drug-eluting stent use on the spectrum of patients undergoing percutaneous coronary intervention. Coron Artery Dis. 2006 May; 17(4):379-84. PMID: 16707962.
      Citations: 1     Fields:    Translation:Humans
    4. Atmakuri SR, Lev EI, Alviar C, Ibarra E, Raizner AE, Solomon SL, Kleiman NS. Initial experience with a magnetic navigation system for percutaneous coronary intervention in complex coronary artery lesions. J Am Coll Cardiol. 2006 Feb 07; 47(3):515-21. PMID: 16458129.
      Citations: 5     Fields:    Translation:Humans
    5. Kleiman NS, Klem J, Fernandes LS, Rubin H, Challa S, Solomon S, Maresh K, Arora U, Klem E, Buergler J, Mathew S, Browning A, DeLao T. Pharmacodynamic profile of the direct thrombin antagonist bivalirudin given in combination with the glycoprotein IIb/IIIa antagonist eptifibatide. Am Heart J. 2002 Apr; 143(4):585-93. PMID: 11923794.
      Citations: 7     Fields:    Translation:HumansCTClinical Trials
    SOLOMON's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (49)
    Co-Authors (3)
    Similar People (60)
    Same Department Expand Description
    Physical Neighbors